glp-1 drugs and thyroid cancer Does drug affect risk? There is no conclusive evidence

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes N Engl J Med

Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications

Function of Akkermansia muciniphila in type 2 diabetes and related diseases

A systematic review and meta-analysis published in eClinicalMedicine found that discontinuing GLP-1 receptor agonist treatment led to an average weight regain of 5.63 kg and 5.81% of body weight across all patients studied

Without the pharmacological support, the body gravitates back toward its previous setpoint

In case youre wondering, the price of safety was rather reasonable